Trulicity (dulaglutide), a once-weekly subcutaneous injection, has been approved by the U.S. Food and Drug Administration to improve glycemic control in adults with type 2 diabetes along with diet and ...
Lilly’s cardiovascular outcomes trial is the first to use an active comparator, finding noninferiority but not superiority of ...
In the AWARD-7 trial, patients who received Trulicity 0.75mg or 1.5mg in combination with mealtime insulin lispro achieved similar glycemic control with weight loss vs patients who received ...
Mounjaro cut all-cause mortality by 16% vs. Trulicity and reduced MACE-3 events by 8% in the SURPASS-CVOT trial. In indirect comparison, Mounjaro lowered MACE-3 risk by 28% and all-cause mortality by ...
@2024 - All Right Reserved.
Mounjaro (tirzepatide) led to greater weight loss and better glucose control than high doses of Trulicity (dulaglutide), according to a study published April 4 in Annals of Internal Medicine. A common ...
A new drug has shown significant promise as an effective diabetes and weight loss treatment—and can be produced more cheaply.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback